Dow Jones
37.753,31 -45,66 (-0,12%) Nasdaq
15.683,37 -181,88 (-1,15%) Nikkei 225
38.141,10 +179,30 (+0,47%) EUR/USD
1,0680 +0,0006 (+0,05%) Bitcoin EUR
57.746,33 -2.390,43 (-3,97%) CMC Crypto 200
885,54 0,00 (0,00%)
Aridis Pharmaceuticals, Inc. (ARDS)
| Chiusura precedente | 0,0705 |
| Aperto | 0,0700 |
| Denaro | 0,0000 x 1000 |
| Lettera | 0,0000 x 1800 |
| Min-Max giorno | 0,0646 - 0,0720 |
| Intervallo di 52 settimane | 0,0500 - 0,5395 |
| Volume | |
| Media Volume | 98.108 |
| Capitalizzazione | 2,942M |
| Beta (5 anni mensile) | 1,03 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,1600 |
| Prossima data utili | 20 mag 2024 - 24 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 2,00 |
GlobeNewswireAridis Pharmaceuticals Announces $2 Million Offering
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced the pricing of an offering of 10,000,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share
- GlobeNewswire
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care (SOC) antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus (S. aureus) in mecha
- GlobeNewswire
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act
